ATLANTA, GA – May 17, 2017 – Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Akari Therapeutics, Plc (“Akari Therapeutics” or the “Company”) (NASDAQ: AKTX) securities between March 30, 2017 and May 11, 2017. The lawsuit alleges that Akari Therapeutics issued certain false and misleading statements that failed to disclose that: (1) Akari Therapeutics’s CEO, and possibly other executives, were involved in publishing false information about Akari Therapeutics, including false information about the Phase 2 PNH trial of Coversin; (2) Akari Therapeutics lacked adequate checks and protections to prevent such behavior; and (3) as a result, defendants’ statements about Akari Therapeutics’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. According to the complaint, Akari Therapeutics’ financial results issued during that time were misleading as a result. If you purchased Akari Therapeutics common stock between March 30, 2017 and May 11, 2017 and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Marshall P. Dees, Esq. at mdees@holzerlaw.com, or by toll-free telephone at (888) 508-6832. The deadline to ask the court to be appointed lead plaintiff is July 11, 2017.

Provide Your Information To Take Action

  • Plaintiff Certifies That:
    1. Plaintiff has reviewed the complaint and authorized its filing.
    2. Plaintiff did not acquire the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this private action or any other litigation under the federal securities laws.
    3. Plaintiff is willing to serve as a representative party on behalf of a class, including providing testimony at deposition and trial, if necessary.
    4. Plaintiff represents and warrants that he/she/it is fully authorized to enter into and execute this certification.
    5. Plaintiff will not accept any payment for serving as a representative party on behalf of a class beyond the Plaintiff's pro rata share of any recovery, except such reasonable costs and expenses (including lost wages) directly relating to the representation of the class as ordered or approved by the court.
    6. Plaintiff has made no transaction(s) during the Class Period in the debt or equity securities that are the subject of this action except those set forth below:
  • Date PurchasedNumber of Shares AcquiredAcquisition Price Per Share 
    Add a new row
  • Date SoldNumber of Shares SoldSelling Price Per Share 
    Add a new row
  • Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.